Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PENG Block in Pediatric Hip Surgery
NCT07607535Not yet recruiting
- Sponsor
- Poznan University of Medical Sciences
- Start
- Jun 2026
- Primary completion
- Jul 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Randomised, double-blind trial of ropivacaine in hip dysplasia (DDH) (2 arms), sponsored by Poznan University of Medical Sciences. Primary endpoint: Systemic Inflammation Response Index at 12 hours. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
ropivacaine
03
Conditions
hip dysplasia (DDH)
Beyond the preview
Go deeper on NCT07607535.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07607535.